References

J Hislop; Z Quayyum; A Elders; C Fraser; D Jenkinson; G Mowatt; P Sharma; L Vale; R Petty

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Hislop J, Quayyum Z, Elders A, et al. Clinical Effectiveness and Cost-Effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable and/or Metastatic Gastrointestinal Stromal Tumours that have Progressed on Treatment at a Dose of 400 Mg/Day: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2011 Jun. (Health Technology Assessment, No. 15.25.)

Cover of Clinical Effectiveness and Cost-Effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable and/or Metastatic Gastrointestinal Stromal Tumours that have Progressed on Treatment at a Dose of 400 Mg/Day: A Systematic Review and Economic Evaluation

Clinical Effectiveness and Cost-Effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable and/or Metastatic Gastrointestinal Stromal Tumours that have Progressed on Treatment at a Dose of 400 Mg/Day: A Systematic Review and Economic Evaluation.

Show details

Contents

< Prev Next >

References

1.: Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–69. [PMC free article: PMC1858579] [PubMed: 9588894]
2.: Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889–94. [PubMed: 15223958]
3.: Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002;38:S39–51. [PubMed: 12528772]
4.: Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 2002;160:1567–72. [PMC free article: PMC1850861] [PubMed: 12000708]
5.: Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004;23:3999–4006. [PubMed: 15007386]
6.: Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484–95. [PubMed: 12094373]
7.: Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–9. [PubMed: 14645423]
8.: Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80. [PubMed: 9438854]
9.: Rubin BP, Fletcher JA, Fletcher CDM. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors. Int J Surg Pathol. 2000;8:5–10. [PubMed: 11493959]
10.: Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61:8118–21. [PubMed: 11719439]
11.: Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 1990;63:213–24. [PubMed: 1698556]
12.: Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–10. [PubMed: 12522257]
13.: Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125:660–7. [PubMed: 12949711]
14.: Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, Van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093–103. [PubMed: 16624552]
15.: Scottish Sarcoma Network. Guidelines for the management of gastrointestinal stromal tumours (GISTs) in Scotland. Glasgow: Scottish Sarcoma Network; 2009. [February 2010]. URL: www.ssn.scot.nhs.uk/protocolsandguidelines/Scottish%20GIST%20guidelines_NOV545_no%.
16.: Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009;33:1401–8. [PubMed: 19606013]
17.: West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107–13. [PMC free article: PMC1618538] [PubMed: 15215166]
18.: Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol. 1995;2:26–31. [PubMed: 7834450]
19.: Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8. [PMC free article: PMC1420965] [PubMed: 10636102]
20.: Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol. 2001;54:96–102. [PMC free article: PMC1731347] [PubMed: 11215292]
21.: Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65. [PubMed: 12094370]
22.: Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999;30:1213–20. [PubMed: 10534170]
23.: Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1–12. [PubMed: 11213830]
24.: Dematteo RP. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol. 2002;9:831–9. [PubMed: 12417503]
25.: Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52–68. [PubMed: 15613856]
26.: Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer. 2005;103:821–9. [PubMed: 15648083]
27.: Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990–2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005;117:289–93. [PubMed: 15900576]
28.: Reichardt P. Practical aspects of managing gastrointestinal stromal tumours. Monogr Gastronintest Stromal Tumours. 2003;1:3–8.
29.: Lehnert T. Gastrointestinal sarcoma (GIST): a review of surgical management. Ann Chir Gynaecol. 1998;87:297–305. [PubMed: 9891770]
30.: Dematteo RP, Heinrich MC, El Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33:466–77. [PubMed: 12094371]
31.: Judson I. A guideline for the management of gastrointestinal stromal tumour (GIST). Sarcoma. 2002;6:83–7. [PMC free article: PMC2395485] [PubMed: 18521337]
32.: Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566–78. [PubMed: 15781488]
33.: Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104. [PMC free article: PMC2915459] [PubMed: 19303137]
34.: Committee for Medicinal Products for Human Use. Monthly report. CHMP/174243/2009. London: European Medicines Agency; 2009. [June 2010]. URL: www.ema.europa.eu/pressoffice/chmp.htm. [PubMed: 19269795]
35.: National Institute for Health and Clinical Excellence (NICE). Imatinib for the adjuvant treatment of gastrointestinal stromal tumours. Final appraisal determination. London: NICE; 2010. [June 2010]. URL: http://guidance.nice.org.uk/TA/Wave20/79/FAD.
36.: Van den Abbeele AD, Badawi RD, Manola J, Morgan JA, Desai J, Kazanovicz A, et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. J Clin Oncol. 2004;22:S3012.
37.: Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42–7. [PMC free article: PMC2606912] [PubMed: 18942073]
38.: Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80. [PubMed: 12181401]
39.: Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–5. [PubMed: 18235121]
40.: Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato dP, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421–3. [PubMed: 11705489]
41.: Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–32. [PubMed: 18235122]
42.: Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34. [PubMed: 15451219]
43.: Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res. 2009;15:7510–18. [PubMed: 20008851]
44.: Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41:1751–7. [PubMed: 16098458]
45.: Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107–13. [PubMed: 17369574]
46.: Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9. [PubMed: 17470865]
47.: Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist. 2008;13:4–7. [PubMed: 18434631]
48.: Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17–21. [PubMed: 14734662]
49.: Van den Abbeele AD. The lessons of GIST: PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13(Suppl. 2):8–13. [PubMed: 18434632]
50.: National Institute for Health and Clinical Excellence (NICE). Gastro-intestinal stromal tumours (GIST) – imatinib. London: NICE; 2004. [August 2009]. NICE Guidance TA86 [document on the Internet] URL: http://guidance.nice.org.uk/TA86/Guidance/pdf/English.
51.: National Institute for Health and Clinical Excellence (NICE). Sunitinib for the treatment of gastrointestinal stromal tumours. London: NICE; 2009. [February 2010]. NICE Guidance TA179 [document on the Internet] URL: www.nice.org.uk/nicemedia/pdf/TA179Guidance.pdf.
52.: Demetri GD, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–38. [PubMed: 17046465]
53.: Pfizer. Safety and effectiveness of daily dosing with sunitinib or imatinib in patients with gastrointestinal stromal tumors. 2006. [February 2010]. ClinicalTrials.gov Identifier NCT00372567. ClinicalTrials. gov. URL: http://clinicaltrials.gov/
54.: Reddy P. The epidemiologic, health-related quality of life, and economic burden of gastrointestinal stromal tumours. J Clin Pharm Ther. 2007;32:557–65. [PubMed: 18021332]
55.: Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess. 2005;9(25) [PubMed: 15985189]
56.: Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). Guidelines for the management of gastrointestinal stromal tumours (GISTs). London: AUGIS; 2005. [February 2010]. URL: www.augis.org/news_guidelines/management_guidelines.htm.
57.: Scottish Medicines Consortium. Imatinib for GIST (Glivec^®). Glasgow: Scottish Medicines Consortium; 2002. [February 2010]. URL: www.scottishmedicines.org.uk/files/GlivecGIST_v2.pdf.
58.: O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597–605. [PubMed: 12531805]
59.: Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res. 2006;12:2622–7. [PubMed: 16638875]
60.: Pfizer. Single Technology Appraisal of sunitinib for the treatment of gastrointestinal stromal tumours. Sandwich, Kent: Pfizer Ltd; 2008. [August 2009]. URL: www.nice.org.uk/guidance/index.jsp?action=download&o=43440.
61.: Ahmed N, Ahmedzai S, Vora V, Hillam S, Paz S. Supportive care for patients with gastrointestinal cancer. Cochrane Database Syst Rev. 2004;1:CD000343. [PMC free article: PMC7173750] [PubMed: 15266485] [CrossRef]
62.: Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352–9. [PMC free article: PMC2651076] [PubMed: 18955458]
63.: Van Glabbeke M, Owzar K, Rankin C, Simes J, Crowley J., GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST): a meta-analysis based on 1640 patients. J Clin Oncol. 2007;25(18S) Abstract 10004.
64.: Demetri G, Wang Y, Wehre E, Blanke C, Joensuu H, von Mehren M. Correlation of imatinib plasma levels with clinical benefit in patients (Pts) with unresectable/metastatic gastrointestinal stromal tumors (GIST). American Society of Clinical Oncology, Gastrointestinal Cancers Symposium; January 2008; Orlando, FL. abstract no. 3.
65.: Egorin MJ, Mauro MJ, Trent JC. Drug plasma monitoring in CML and GIST: a case-based discussion. Clin Adv Hematol Oncol. 2009;7:S1–11. [PubMed: 20099379]
66.: Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, et al. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer. 2008;98:1633–40. [PMC free article: PMC2391118] [PubMed: 18475296]
67.: Novartis. Glivec: summary of product characteristics. The Electronic Medicines Compendium; 2009. [February 2010]. URL: http://emc.medicines.org.uk/history/15014/SPC/GLIVEC+Tablets#03/06/2009%20to%20Current.
68.: Rankin C, von Mehren M, Blanke C, Benjamin R, Fletcher CDM, Bramwell V, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST: phase III Sarcoma Group Study S0033. J Clin Oncol. 2004;22(14S) Abstract 9005.
69.: Centre for Reviews and Dissemination (CRD). Systematic reviews: CRD's guidance for undertaking systematic reviews in health care. University of York: Centre for Reviews and Dissemination; 2009. [January 2010]. URL: www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm.
70.: Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51:1235–41. [PubMed: 10086815]
71.: Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–84. [PMC free article: PMC1756728] [PubMed: 9764259]
72.: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.0.2. The Cochrane Collaboration; 2009. [January 2010]. URL: www.cochrane-handbook.org.
73.: Parmar MK, Torri V, Stewary L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34. [PubMed: 9921604]
74.: Yusuf S, Peto R, Lewis J, Colins R, Sleight P. Beta blockade during and after myocardial infarction. An overview of randomized trials. Prog Cardiovasc Dis. 1985;27:335–71. [PubMed: 2858114]
75.: Droitcour J, Silberman G, Chelimsky E. Cross-design synthesis: a new form of meta-analysis for combining results from randomized clinical trials and medical-practice databases. Int J Technol Assess Health Care. 1993;9:440–9. [PubMed: 8340208]
76.: Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48. [PubMed: 13655060]
77.: Dileo P, Rankin CJ, Benjamin RS, von Mehren M, Blanke C, Bramwell V, et al. Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2005;23(Suppl. 16):824.
78.: Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD): an international, intergroup study of the EORTC, ISG and AGITG. J Clin Oncol. 2004;22(Suppl. 14):9004.
79.: Park I, Ryu MH, Sym SJ, Lee SS, Jang G, Kim TW, et al. Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. Jpn J Clin Oncol. 2009;39:105–10. [PubMed: 19052040]
80.: Kang Y, Reichardt P, Ruka W, Seddon B, Baum C, Demetri G. Efficacy and safety of sunitinib in a worldwide treatment-use trial of GIST patients following imatinib failure. Ann Oncol. 2007;18(Suppl. 7):vii16. Abstract O-0017.
81.: Reichardt P, Kang Y, Ruka W, Seddon B, Nieto A, Breazna A, et al. Sunitinib (Su) in a worldwide treatment-use trial of patients with GIST: updated efficacy and safety analysis. Ann Oncol. 2008;19(Suppl. 8):viii267. Abstract 869PD.
82.: Reichardt P, Kang Y, Ruka W, Seddon B, Guerriero A, Breazna A, et al. Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. J Clin Oncol. 2008;26(Suppl. 15) Abstract 10548.
83.: Rutkowski P, Reichardt P, Kang Y, Ruka W, Seddon B, Guerriero A, et al. Sunitinib in a worldwide treatment-use trial of patients with imatinib-resistant/intolerant gastrointestinal stromal tumor: detailed analysis of survival and safety. Ann Oncol. 2008;19(Suppl. 6):vii12. Abstract O-013.
84.: Schutte J, Reichardt P, Schlemmer M, Wendtner CM, Demetri GD. Efficacy and safety of sunitinib in patients with gastrointestinal stromal tumour resistant or intolerant of prior imatinib therapy: results from a worldwide treatment-use study. Onkologie. 2008;31(Suppl. 1):77. Abstract OP130.
85.: Seddon B, Reichardt P, Ruka W, Kang YK, Baum CM, Demetri GD. Safety and efficacy results of sunitinib from a worldwide treatment use trial of gastrointestinal stromal tumour (GIST) patients (pts) with resistance or intolerance to prior imatinib therapy. Eur J Cancer. 2007;5:S405. Abstract 7511.
86.: Seddon B, Reichardt P, Kang YK, Ruka W, Nieto A, Breazna A, et al. Detailed anlaysis of survival and safety with sunitinib in a worldwide treatment-use trial of patients with advanced imatinib-resistant/intolerant GIST. Connective Tissue Oncology Society, 14th Annual Meeting; November 2008; London. abstract no. 34980.
87.: An JY, Choi MG, Noh JH, Sohn TS, Kang WK, Park CK, et al. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease. Eur J Surg Oncol. 2007;33:1030–5. [PubMed: 17428635]
88.: Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011–19. [PMC free article: PMC2643085] [PubMed: 18083403]
89.: Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Molecul Imag. 2005;32:153–62. [PMC free article: PMC2706372] [PubMed: 15690223]
90.: Nishida T, Shirao K, Sawaki A, Koseki M, Okamura T, Ohtsu A, et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol. 2008;13:244–51. [PubMed: 18553235]
91.: Phongkitkarun S, Phaisanphrukkun C, Jatchavala J, Sirachainan E. Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate. World J Gastroenterol. 2008;14:892–8. [PMC free article: PMC2687056] [PubMed: 18240346]
92.: Arends LR, Hunink MG, Stijnen T. Meta-analysis of summary survival curve data. Stat Med. 2008;27:4381–96. [PubMed: 18465839]
93.: Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36) [PubMed: 15361314]
94.: National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2008. [February 2010]. URL: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf.
95.: Chabot I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. Eur J Cancer. 2008;44:972–7. [PubMed: 18372169]
96.: Contreras-Hernandez I, Mould-Quevedo JF, Silva A, Salinas-Escudero G, Villasis-Keever MA, Granados-Garcia V, et al. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. Br J Cancer. 2008;98:1762–8. [PMC free article: PMC2410103] [PubMed: 18506179]
97.: Huse DM, von Mehren M, Lenhart G, Joensuu H, Blanke C, Feng W, et al. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clin Drug Invest. 2007;27:85–93. [PubMed: 17217313]
98.: Mabasa VH, Taylor SCM, Chu CCY, Moravan V, Johnston K, Peacock S, et al. Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study). J Oncol Pharm Pract. 2008;14:105–12. [PubMed: 18524863]
99.: Paz-Ares L, Garcia del Muro X, Grande E, Gonzalez P, Brosa M, Diaz S. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clin Trans Oncol. 2008;10:831–9. [PubMed: 19068454]
100.: Teich N, Hashizume C, Follador W. Economic evaluation of sunitinib vs. imatinib in second line for gastrointestinal tumor (GIST) in Brazil. Value Health. 2009;12:A496.
101.: Hopkins TG, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol. 2008;34:844–50. [PubMed: 18082353]
102.: Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichard P, Blay J, et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG abstract. 39th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL. 31 May to 3 June 2003; abstract no. 3272.
103.: Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg BL, Fletcher J, et al. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate. J Clin Oncol. 2006;24(18S) Abstract 9528.
104.: Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs. 2006;15:553–61. [PubMed: 16634693]
105.: Ojeda B, de Sande LM, Casado A, Merino P, Casado MA. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br J Cancer. 2003;89:1002–7. [PMC free article: PMC2376947] [PubMed: 12966416]
106.: McGrath PC, Neifeld JP, Lawrence W Jr, Kay S, Horsley JS III, Parker GA. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg. 1987;206:706–10. [PMC free article: PMC1493319] [PubMed: 3689007]
107.: Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001;136:383–9. [PubMed: 11296107]
108.: Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27:439–45. [PubMed: 19064982]
109.: British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 58. London: BMA and RPS; Sep, 2009. 2009.
110.: Curtis L. Unit costs of health and social care 2009. Canterbury: Personal Social Services Research Unit; 2009. [February 2010]. URL: www.pssru.ac.uk/uc/uc.htm.
111.: Nilsson B, Nilsson O, Ahlman H. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib: and then? Expert Opin Investig Drugs. 2009;18:457–68. [PubMed: 19335275]
112.: Dougherty MJ, Compton C, Talbert M, Wood WC. Sarcomas of the gastrointestinal tract. Separation into favorable and unfavorable prognostic groups by mitotic count. Ann Surg. 1991;214:569–74. [PMC free article: PMC1358612] [PubMed: 1953109]
113.: Artinyan A, Kim J, Soriano P, Chow W, Bhatia S, Ellenhorn JD. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. Cancer Epidemiol Biomarkers Prev. 2008;17:2194–201. [PubMed: 18708414]
114.: Casali PG. Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:iv64–7. [PubMed: 19454466]
115.: Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST): update of the NCCN clinical practice guidelines. J Natl Compr Cancer Netw. 2007;5(Suppl. 2):S1–29. [PubMed: 17624289]
116.: Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55. [PubMed: 7165009]
117.: Blanke CD, Joensuu H, Demetri GD, Heinrich MC, Eisenberg B, Fletcher J, et al. Outcome of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate: four year follow-up of a phase II randomized trial. J Clin Oncol. 2006;24(Suppl.):18S. [abstract]
118.: Maki R, Fletcher JA, Heinrich M, Morgan JA, George S, Desai J, et al. Results from a continuation trial of SU11248 in patients with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol. 2005;23(Suppl.) Abstract 9011.
119.: George S, Blay J, Casali P, Le Cesne A, Morgan J, Pokela J, et al. Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in patients with advanced GIST. J Clin Oncol. 2007;25(Suppl. 18) Abstract 10015.
120.: Scottish Medicines Consortium. Sunitinib 50 mg capsule (Sutent) No.275/06. 2006. URL: www.scottishmedicines.org.uk/SMC_Advice/Advice/Sunitinib__Sutent_/sunitinib_50mg_capsule__Sutent_.
121.: de Mestier P, des Guetz G. Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics. World J Surg. 2005;29:357–61. [PubMed: 15706444]
122.: von Mehren M. Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies. Curr Oncol Rep. 2006;8:192–7. [PubMed: 16618383]
123.: Plaat BE, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol. 2000;18:3211–20. [PubMed: 10986053]
124.: Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol. 2000;7:705–12. [PubMed: 11034250]
125.: Comandone A, Boglione A. Biology, diagnosis and therapeutic options in gastrointestinal stromal tumours. Minerva Chir. 2005;60:197–203. [PubMed: 16166919]
126.: Duffaud F, Blay JY. Gastrointestinal stromal tumors: biology and treatment. Oncology. 2003;65:187–97. [PubMed: 14657591]
127.: Cohen MH, Dagher R, Griebel DJ, Ibrahim A, Martin A, Scher NS, et al. US Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist. 2002;7:393–400. [PubMed: 12401901]
128.: Totman MB. Imatinib for gastrointestinal stromal tumours. In: Bazian Ltd, editor. STEER: Succinct and Timely Evaluated Evidence Reviews. Southampton: Wessex Institute for Health Research & Development, University of Southampton; 2002.
129.: Katz SC. Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol. 2008;97:350–9. [PubMed: 18286477]
130.: Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 2003;98:2693–9. [PubMed: 14669291]
131.: Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. 2009;27:3969–74. [PMC free article: PMC2799153] [PubMed: 19620483]

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK99518

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Hislop J, Quayyum Z, Elders A, et al. Clinical Effectiveness and Cost-Effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable and/or Metastatic Gastrointestinal Stromal Tumours that have Progressed on Treatment at a Dose of 400 Mg/Day: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2011 Jun. (Health Technology Assessment, No. 15.25.) References.
PDF version of this title (1.5M)

Other titles in this collection

Health Technology Assessment

Related information

PMC
PubMed Central citations
PubMed
Links to PubMed

Recent Activity

Clear Turn Off Turn On

References - Clinical Effectiveness and Cost-Effectiveness of Imatinib Dose Esca...
References - Clinical Effectiveness and Cost-Effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable and/or Metastatic Gastrointestinal Stromal Tumours that have Progressed on Treatment at a Dose of 400 Mg/Day: A Systematic Review and Economic Evaluation

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Clinical Effectiveness and Cost-Effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable and/or Metastatic Gastrointestinal Stromal Tumours that have Progressed on Treatment at a Dose of 400 Mg/Day: A Systematic Review and Economic Evaluation.

References

Views

Other titles in this collection

Related information

Recent Activity